AusperBio, a sino-American developer specializing in liver therapies, has announced that its drug candidate AHB-137 is on track to receive breakthrough therapy designation (BTD) in China for the treatment of chronic hepatitis B virus (HBV). AHB-137 is a highly potent, pan-genotypic antisense oligonucleotide (ASO) that targets all HBV RNA, positioning it as a potential best-in-class treatment for patients with chronic HBV.
Developed on AusperBio’s proprietary Med-Oligo platform, AHB-137 is currently under investigation in a global, multi-center Phase I study, as well as a Phase II study in China. These clinical trials aim to evaluate the safety, tolerability, and efficacy of the drug candidate in treating chronic HBV infection.- Flcube.com
